Clinical Trials Directory

Trials / Conditions / Skin and Connective Tissue Diseases

Skin and Connective Tissue Diseases

14 registered clinical trials studyying Skin and Connective Tissue Diseases — 2 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingEarly Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by F
NCT07506967
Kenya Medical Research InstituteN/A
RecruitingTreatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons with Diabetes
NCT06427889
Malmö UniversityPhase 4
Active Not RecruitingAssessment of Circulating Fubctional Mitochondrias in Vitiligo Patients
NCT05525741
Centre Hospitalier Universitaire de NiceN/A
Active Not RecruitingResidual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLA
NCT05185258
Aarhus University HospitalPhase 4
CompletedPilot Study Assessing the Effect of Tildrakizumab in Vitiligo
NCT04971200
Premier Specialists, AustraliaEARLY_Phase 1
WithdrawnBiomarker for Hyaline Fibromatosis Syndrome (BioHFS)
NCT03196115
CENTOGENE GmbH Rostock—
CompletedSafety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin
NCT02985437
Prof. Dr. Dr. Ursula MirastschijskiPhase 1
CompletedA Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
NCT02518048
LEO PharmaPhase 2
CompletedA Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
NCT02416258
LEO PharmaPhase 2
CompletedSkin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects
NCT02379793
LEO PharmaPhase 1
CompletedA Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
NCT02355639
LEO PharmaPhase 1
CompletedSafety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
NCT01764594
UCB PharmaPhase 1
CompletedSafety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
NCT01093911
UCB PharmaPhase 1
CompletedTime To Efficacy and Onset Of Action Of Linezolid
NCT00147511
PfizerPhase 4